LYEL
Lyell Immunopharma, Inc.Healthcare·Biotechnology
$17.33
$404M market cap
Revenue
$0.0M
Free Cash Flow
$-71.2M
Rev Growth
+0.0%
FCF Margin
-889425.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer an
2-Year Price History
$17.46-68.5%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.0 | -43.8 | -46.2 | -24.2 | -38.5 | -38.6 | -0.1 | 254.0 | 39.5 | 21.9 | -127.9% | -- | -- |
| Act | 2025-Q4 | 0.0 | -58.9 | -61.3 | -140.7 | -32.3 | -32.6 | -0.3 | 247.2 | 41.9 | 17.1 | -200.1% | -- | -- |
Valuation & Metrics
Market Stats
Price$17.33
Market Cap$404M
Enterprise Value$190M
P/S Ratio50547.5x
P/FCF--
EV/FCF--
FCF Margin (TTM)-889425.0%
FCF Yield-17.6%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-164.9M
Free Cash Flow$-71.2M
Revenue Growth (YoY)+0.0%
EBITDA Margin-1284250.0%
Net Margin-2060950.0%
FCF Margin-889425.0%
CapEx % of Revenue4912.5%
SBC % of Revenue319612.5%
ROIC-164.0%
WC Change % Rev32187.5%
Interest Coverage--
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares1.3M
Days to Cover18.8
Change (vs Prior)+8.9%
Need at least 2 settlement dates for chart
Employees
Headcount300
Revenue / Employee$27
Gross Profit / Employee$-7,747
Cash Runway
42.8months
WATCH
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
49.8%(+36.6% YoY)
58 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
6.6%(+5.0% YoY)
9 filers
Vanguard, iShares, SPDR
Market makers
2.0%(+1.9% YoY)
5 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| ARCH Venture Management, LLC | $65.1M | $12.67 | +$9.8M | +$65.1M | -6.7% | $677M |
| GSK plc | $30.3M | $30.78 | +$0 | +$30.3M | -20.9% | $599M |
| Foresite Capital Management IV, LLC | $16.1M | $8.84 | +$0 | +$16.1M | -3.5% | $237M |
| Orland Properties Ltd | $15.1M | $16.24 | +$0 | +$15.1M | -1.0% | $267M |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $14.4M | $20.06 | +$14.4M | +$14.4M | — | $4.04T |
| Almitas Capital LLC | $11.6M | $8.84 | +$0 | +$11.6M | +2.5% | $442M |
| Foresite Capital Management V, LLC | $9.6M | $9.93 | +$0 | +$9.6M | -1.6% | $271M |
| MILLENNIUM MANAGEMENT LLC | $9.2M | $18.41 | +$8.0M | +$9.2M | -0.5% | $127.40B |
| CITADEL ADVISORS LLC | $7.7M | $11.72 | +$1.1M | +$7.7M | -0.4% | $138.22B |
| venBio Partners LLC | $6.8M | $8.84 | +$0 | +$6.8M | -3.0% | $281M |
| SUSQUEHANNA INTERNATIONAL GROUP, LLPMM | $6.2M | $24.52 | +$3.2M | +$6.2M | -0.6% | $77.14B |
| Alphabet Inc. | $5.9M | $8.84 | +$0 | +$5.9M | +0.2% | $4.02B |
| BlackRock, Inc.Passive | $3.8M | $11.23 | +$200K | +$3.8M | -0.2% | $5.69T |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $3.4M | $14.61 | +$80K | +$3.4M | +2.3% | $1.61T |
| MARSHALL WACE, LLP | $3.0M | $23.79 | +$1.5M | +$3.0M | +0.6% | $92.71B |
| RENAISSANCE TECHNOLOGIES LLC | $2.3M | $14.83 | +$1.5M | +$2.3M | +1.2% | $63.91B |
| GOLDMAN SACHS GROUP INC | $2.3M | $29.11 | +$357K | +$2.3M | -0.2% | $760.93B |
| Velan Capital Investment Management LP | $2.0M | $20.06 | +$2.0M | +$2.0M | -5.3% | $160M |
| MIC Capital Management UK LLP | $1.7M | $8.84 | +$0 | +$1.7M | -2.3% | $352M |
| VANGUARD FIDUCIARY TRUST COPassive | $1.7M | $20.06 | +$1.7M | +$1.7M | — | $395.83B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BEARISH
Holders
-5.90%
avg per quarter
Holders (ex-self)
-5.83%
excl. this stock
Buyers (this Q)
-0.66%
28 buyers · $0.04B in
Sellers (this Q)
+1.21%
9 sellers · $0.00B out
alpha coverage: 93% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
+7.5%
how holders react when this stock falls
On quiet Qs
-5.1%
−10% to +10% baseline
On rallies (+10%+)
-5.1%
how they react when this stock rises
Holders' portfolio flow this Q
-1.4%
outflows — trims may be forced
Sellers' portfolio flow this Q
+11.7%
Sellers grew AUM elsewhere — opinionated cut of this stock.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-3.0%
Holder mid (any stock)
-5.1%
Holder rally (any stock)
-8.2%
Biggest decreases this quarter
HSG Holding Ltdexited−$3.9MInvesco Ltd.exited−$3.0MJOHNSON & JOHNSONexited−$1.7MBOOTHBAY FUND MANAGEMENT, LLCexited−$293KExodusPoint Capital Management, LPexited−$262KRAYMOND JAMES FINANCIAL INCexited−$243KCandriam Luxembourg S.C.A.exited−$234KACADIAN ASSET MANAGEMENT LLCexited−$51KDaiwa Securities Group Inc.exited−$1K
New buyers this quarter
Top-5 holders · 59.5%
ARCH Venture Management, LLC--
GSK plc--
Foresite Capital Management IV, LLC--
Orland Properties Ltd--
VANGUARD CAPITAL MANAGEMENT LLC--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
ARCH Venture Management, LLC3.2MGSK plc1.5MMWG Caph Ltd—Foresite Capital Management IV, LLC800KOrland Properties Ltd755KAlmitas Capital LLC578KMWG Management Ltd.—Foresite Capital Management V, LLC477KvenBio Partners LLC338KCITADEL ADVISORS LLC381K
Related Stocks
Investors who own this also own
Stocks held by the same active managers as this one, ranked by score — how much more often these appear together than random chance (1× = baseline). Excludes index ETFs and market makers; minimum 3 shared holders.
Analyst Coverage
Analyst Coverage
Price Targets
Last Quarter (2 analysts)$46.5016830.0%
Last Year (4 analysts)$39.5012790.0%
Current Price$17.33
Analyst Ratings
2
3
1
Buy: 2Hold: 3Sell: 1Consensus: Hold
Corporate
Insider Trading (last 12mo)
Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Officers & directors
Buys ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Sells ($, 12mo)
$486K
25 txns · 5 insiders · 26,949 sh
Major holders (≥10% beneficial owners)
Buys ($, 12mo)
$25.00M
2 txns · 2 insiders · 976,180 sh
Sells ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Recent transactions
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2026-03-06 | BUY | ARCH Venture Fund XIII, L.P. | 10 percent owner | 488,090 | $25.61 | $12.50M | $36.53M |
| 2026-03-06 | BUY | ARCH Venture Partners IX, LLC | 10 percent owner | 488,090 | $25.61 | $12.50M | $36.53M |
| 2026-02-11 | SELL | Hill Stephen J. | officer: Chief Operating Officer | 1,236 | $23.39 | $29K | $416K |
| 2026-02-11 | SELL | Lee Gary K. | officer: Chief Scientific Officer | 1,671 | $23.39 | $39K | $396K |
| 2026-02-11 | SELL | Seely Lynn | director, officer: President and CEO | 7,455 | $23.39 | $174K | $1.74M |
| 2026-02-10 | SELL | Bulis Veronica Sanchez | officer: VP, Corporate Controller | 254 | $23.12 | $6K | $362K |
| 2026-02-10 | SELL | Hill Stephen J. | officer: Chief Operating Officer | 109 | $23.12 | $3K | $440K |
| 2026-02-10 | SELL | Lee Gary K. | officer: Chief Scientific Officer | 147 | $23.12 | $3K | $430K |
| 2026-02-10 | SELL | Seely Lynn | director, officer: President and CEO | 438 | $23.12 | $10K | $1.89M |
| 2025-12-30 | SELL | Bulis Veronica Sanchez | officer: VP, Corporate Controller | 936 | $32.32 | $30K | $231K |
| 2025-12-24 | SELL | Bulis Veronica Sanchez | officer: VP, Corporate Controller | 1,136 | $38.67 | $44K | $312K |
| 2025-11-10 | SELL | Seely Lynn | director, officer: President and CEO | 412 | $16.11 | $7K | $1.08M |
| 2025-11-10 | SELL | Lee Gary K. | officer: Chief Scientific Officer | 138 | $16.16 | $2K | $248K |
| 2025-11-10 | SELL | Hill Stephen J. | officer: Chief Operating Officer | 95 | $16.12 | $2K | $254K |
| 2025-11-10 | SELL | Bulis Veronica Sanchez | officer: VP, Corporate Controller | 239 | $16.10 | $4K | $148K |
| 2025-08-21 | SELL | Hill Stephen J. | officer: Chief Operating Officer | 1,004 | $10.54 | $11K | $167K |
| 2025-08-21 | SELL | Lee Gary K. | officer: Chief Scientific Officer | 1,453 | $10.54 | $15K | $163K |
| 2025-08-21 | SELL | Newton Charles W. | officer: Chief Financial Officer | 1,453 | $10.54 | $15K | $161K |
| 2025-08-21 | SELL | Seely Lynn | director, officer: President and CEO | 7,257 | $10.54 | $77K | $712K |
| 2025-08-12 | SELL | Hill Stephen J. | officer: Chief Operating Officer | 94 | $10.34 | $972 | $91K |
Order Flow (FINRA, ~3w lag)
7.1%retail-2.0pp
19.3%dark-2.9pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
Lyell Immunopharma: High-Burn Asset Acquisition Vehicle with Structural Dilution
Overall Risk
8/10
Fraud
3/10
Dilution
10/10
Insolvency
6/10
Earnings Overstated
2/10
Hidden Liabilities
5/10
Legal
3/10
Audit Warnings
4/10
Hidden Upside
3/10
Contextually Acceptable
5/10